Evidence map›Paper›PMID 35990221›Full record

ReviewCanadian liver journal2019

Cannabis and the liver: Things you wanted to know but were afraid to ask.

Julie Zhu, Kevork M Peltekian

Open access · greenAbstract readReview
In one paragraph

Review in Canadian liver journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Subchronic Exposure to Low-Dose Cannabidiol (CBD) and ΔPathophysiology : the official journal of the International Society for Pathophysiology · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Cannabinoids and Chronic Liver Diseases.International journal of molecular sciences · 2022
    Review
  9. Tobacco, cannabis, and the liver.Clinical liver disease
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 2 countries.

Julie ZhuDivision of Digestive Care & Endoscopy, Dalhousie University and Atlantic Multi-Organ Transplantation Program, QEII Health Sciences Centre, Halifax, Nova Scotia.
Kevork M PeltekianDivision of Digestive Care & Endoscopy, Dalhousie University and Atlantic Multi-Organ Transplantation Program, QEII Health Sciences Centre, Halifax, Nova Scotia.
Dalhousie University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many Canadians use cannabis for medicinal and recreational purposes. We describe the current understandings of how cannabis is metabolized in the liver and its potential interactions with other common drugs. We also summarize how cannabis may exert various effects in chronic liver diseases (CLDs), especially in chronic hepatitis C virus (HCV) and fatty liver disease.

Indexed as

cannabidiolcannabischronic liver diseasepharmacokineticstetrahydrocannabinol

Identifiers

PMID35990221
PMCPMC9202751
OpenAlexW2916894329

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.